Nodular Pulmonary Amyloidosis Mimicking Lung Cancer: CT and FDG PET/CT Findings
Author: Dr. HJ Lee
Executive Answer
Nodular pulmonary amyloidosis is a rare form of localized pulmonary amyloid deposition that can closely mimic primary lung cancer on CT and FDG PET/CT. In this case, a woman in her 70s undergoing evaluation for arrhythmia was found to have an approximately 2-cm left apical, pleural-adjacent pulmonary nodule with spiculated margins and eccentric calcification. FDG PET/CT demonstrated increased uptake with an SUVmax of 4.7. Although these findings raised substantial concern for malignancy, the final diagnosis was nodular pulmonary amyloidosis, specifically kappa-type AL amyloidosis. The key lesson is that calcification, spiculation, and FDG uptake must be interpreted together rather than treated as independent proof of cancer.
Why This Case Matters
A calcified pulmonary nodule is not automatically benign.
That principle is particularly important when a nodule contains eccentric rather than classic benign calcification, has an irregular or spiculated margin, is located in the upper lobe, and demonstrates increased metabolic activity on FDG PET/CT.
This case illustrates a difficult but clinically important diagnostic problem: a rare benign or localized amyloid-related process can reproduce several imaging features that normally increase suspicion for lung cancer.
The case therefore has value beyond the diagnosis of amyloidosis itself. It demonstrates how radiologists should integrate:
Nodule size
Anatomic location
Margin characteristics
Calcification pattern
Multiplanar CT appearance
FDG uptake
Clinical risk factors
Pathologic confirmation
The possibility of localized versus systemic amyloidosis
The original case describes an approximately 2-cm nodule near the left lung apex, with spiculation and eccentric calcification, followed by FDG uptake with an SUVmax of 4.7. The final diagnosis was nodular pulmonary amyloidosis, kappa-type AL amyloidosis.
Clinical Scenario
A woman in her 70s presented for evaluation of arrhythmia. Electrocardiographic evaluation demonstrated bifascicular block and atrial fibrillation.
During the clinical evaluation, a chest radiograph revealed a subtle nodular opacity in the left lung apex. Further imaging was performed to determine whether this represented a true pulmonary lesion.
Importantly, the available clinical information does not establish that the arrhythmia was caused by pulmonary amyloidosis.
That distinction matters.
Cardiac amyloid involvement may need to be considered in an appropriate clinical setting, particularly when conduction abnormalities or other concerning cardiac findings are present. However, the simultaneous presence of an arrhythmia and a pulmonary nodule is not sufficient evidence of a causal relationship. The pulmonary lesion and cardiac findings should be evaluated as related or unrelated clinical problems until additional evidence establishes otherwise.
Imaging Findings
Chest Radiograph: The Initial Clue
The initial chest radiograph demonstrated a small nodular opacity projected over the left lung apex.
A subtle apical opacity can be difficult to characterize on radiography because the lung apex contains overlapping structures, including the clavicles, ribs, pleura, and vascular structures.
Therefore, a small apical opacity on a chest radiograph should not automatically be dismissed as an artifact or superimposed structure.
When a pulmonary nodule is suspected, comparison with prior imaging and cross-sectional CT are important next steps.
Figure 1. Chest PA radiograph
Caption: Chest radiograph demonstrating a subtle nodular opacity in the left lung apex. The radiographic appearance is limited by overlapping apical structures, making CT correlation important.
Suggested ALT text: Chest PA radiograph showing a subtle left apical pulmonary nodule.
CT Findings: The Nodule Becomes More Suspicious
Noncontrast chest CT demonstrated a pulmonary nodule adjacent to the pleura in the left lung apex.
The lesion measured approximately 2 cm and contained an internal high-attenuation component consistent with calcification.
The important imaging features were not simply the presence of calcification, but the combination of:
Upper-lobe/apical location
Pleural adjacency
Approximately 2-cm size
Irregular morphology
Spiculated margin
Eccentric calcification
These features create a substantially different diagnostic problem from a small, densely and centrally calcified granuloma.
The CT appearance therefore raised concern for a malignant pulmonary nodule even though calcification was present.
Axial Chest CT
Figure 2. Noncontrast axial chest CT
Caption: Axial noncontrast CT demonstrates a pleural-adjacent nodule in the left lung apex with an internal high-attenuation component. Nodule morphology and the distribution of calcification should be assessed together.
Suggested ALT text: Axial noncontrast chest CT showing a calcified left apical pulmonary nodule adjacent to the pleura.
Coronal CT Reconstruction: Why Multiplanar Imaging Matters
Coronal reconstruction confirmed the superior-inferior extent of the lesion and its relationship to the pleura, chest wall, and adjacent lung parenchyma.
Multiplanar reconstruction is particularly useful for apical lesions because a single axial image can sometimes make pleural thickening, scarring, or adjacent structures appear more nodular than they actually are.
The lesion should therefore be confirmed across multiple planes before its morphology is characterized as truly spiculated or mass-like.
Figure 3. Coronal chest CT reconstruction
Caption: Coronal CT reconstruction demonstrates the left apical pleural-adjacent nodule and helps define its three-dimensional relationship to the pleura and surrounding structures.
Suggested ALT text: Coronal chest CT reconstruction showing a pleural-adjacent left apical pulmonary nodule.
Lung Window CT: Spiculation and Eccentric Calcification
On lung-window images, the lesion demonstrated an irregular contour with protruding or spiculated components.
Spiculation is an important imaging feature because it increases suspicion for primary lung malignancy. However, spiculation is not synonymous with cancer.
Irregular margins may also occur in inflammatory, fibrotic, and other nonmalignant lesions.
This case demonstrates exactly why a radiologist should avoid a one-feature diagnosis.
Spiculation increases concern for malignancy, but it does not establish malignancy.
Likewise, calcification can provide useful diagnostic information, but its mere presence does not establish benignity.
Figure 4. Axial chest CT, lung window
Caption: Lung-window CT highlights the irregular and spiculated contour of the left apical nodule and the internal high-attenuation component.
Suggested ALT text: Lung-window axial CT showing a spiculated left apical pulmonary nodule with internal calcification.
How Should Calcification in a Pulmonary Nodule Be Interpreted?
Calcification is often associated with benign pulmonary lesions, but the pattern of calcification matters.
Commonly recognized patterns include:
| Calcification pattern | General interpretation |
|---|---|
| Central | May favor a benign granulomatous process |
| Diffuse | Often associated with benign disease |
| Laminated | May reflect a healed granulomatous process |
| Popcorn-like | Can suggest pulmonary hamartoma |
| Punctate | Nonspecific |
| Eccentric | Does not exclude malignancy |
The key distinction is that eccentric calcification is not a reliable “benign” sign.
In this case, eccentric calcification occurred together with an irregular, spiculated morphology. That combination warranted further evaluation rather than reassurance based on calcification alone.
Figure 5. Axial chest CT, lung window
Caption: An additional axial CT image demonstrates the internal high-attenuation component and irregular nodule margin. The distribution of calcification should be assessed in relation to the overall morphology.
Suggested ALT text: Axial lung-window CT demonstrating eccentric calcification within a spiculated left apical pulmonary nodule.
FDG PET/CT: SUVmax 4.7 Does Not Equal Cancer
F-18 fluorodeoxyglucose (FDG) PET/CT demonstrated increased FDG uptake corresponding to the left apical pulmonary nodule.
The reported SUVmax was 4.7.
This finding increases concern for a metabolically active lesion, but it does not establish a malignant diagnosis.
This is one of the most important lessons from the case.
FDG uptake is not cancer-specific. Increased uptake can occur with inflammatory and infectious processes and has also been reported in nodular pulmonary amyloidosis.
Therefore, SUVmax should be interpreted in the context of:
Nodule size
Margin morphology
Calcification pattern
Location
Clinical risk factors
Prior imaging
Other imaging findings
The possibility of nonmalignant metabolic activity
The source case specifically emphasizes that increased FDG uptake in nodular pulmonary amyloidosis can mimic malignancy.
Figure 6. F-18 FDG PET and fused PET/CT
Caption: F-18 FDG PET/CT demonstrates increased FDG uptake corresponding to the left apical pulmonary nodule, with a reported SUVmax of 4.7.
Suggested ALT text: F-18 FDG PET/CT showing increased metabolic activity in a left apical pulmonary nodule with SUVmax 4.7.
Radiologist's Reasoning: Why Lung Cancer Was a Reasonable Concern
The imaging findings in this case reasonably raised concern for primary lung cancer.
Several features point toward malignancy:
The patient was in her 70s.
The lesion was located in the upper lung/apical region.
The lesion was approximately 2 cm.
The margin was irregular and spiculated.
Calcification was eccentric rather than a classic benign pattern.
FDG uptake was increased on PET/CT.
A radiologist should therefore not dismiss the lesion as benign simply because calcification is present.
At the same time, the radiologist should recognize that none of these findings is individually diagnostic of cancer.
The correct interpretation is probabilistic rather than absolute:
The imaging features increase the probability of malignancy, but the imaging pattern is not specific enough to establish malignancy.
That distinction becomes critical when a rare mimic such as nodular pulmonary amyloidosis is ultimately identified.
What Is Nodular Pulmonary Amyloidosis?
Amyloidosis refers to a group of disorders characterized by deposition of abnormally folded proteins as insoluble amyloid fibrils within tissues.
Pulmonary amyloidosis can take several forms, including:
Nodular pulmonary amyloidosis
Diffuse alveolar-septal amyloidosis
Tracheobronchial amyloidosis
Nodular pulmonary amyloidosis is characterized by one or more localized pulmonary nodules.
The nodules may be smooth and relatively well-defined, but some lesions become irregular and can closely resemble primary lung cancer.
Calcification may also occur.
This combination explains why nodular pulmonary amyloidosis can become a significant differential diagnosis for an apparently malignant pulmonary nodule.
AL Amyloidosis Versus ATTR Amyloidosis
Amyloid type matters.
AL amyloidosis results from immunoglobulin light-chain-derived amyloid proteins.
ATTR amyloidosis results from transthyretin-derived amyloid proteins.
These are biologically distinct diseases and can have different clinical implications and treatment approaches.
Therefore, identification of amyloid deposition alone is not sufficient to classify the disease. The amyloid protein type must be established when clinically appropriate.
In this case, the final diagnosis was described as kappa-type AL amyloidosis. However, the presence of kappa-type AL amyloid does not by itself establish systemic amyloidosis. Localized pulmonary disease and systemic disease must be distinguished through appropriate clinical evaluation.
Differential Diagnosis of a Calcified Spiculated Pulmonary Nodule
1. Primary Lung Cancer
Primary lung cancer remains an important consideration when a pulmonary nodule is spiculated, upper-lobe predominant, enlarging, or associated with other clinical risk factors.
Importantly, some lung cancers can contain calcification.
Therefore:
Calcification does not automatically exclude lung cancer.
2. Metastatic Pulmonary Nodule
Metastatic disease can produce multiple pulmonary nodules, although a solitary lesion can occur.
Certain tumors, including some sarcomas, may produce calcified or ossified pulmonary metastases.
A history of malignancy therefore changes the pretest probability and should be integrated with the nodule's size, morphology, distribution, and temporal behavior.
3. Pulmonary Hamartoma
A pulmonary hamartoma is a common benign pulmonary tumor.
The combination of macroscopic fat and characteristic popcorn-like calcification can be highly suggestive.
However, not every hamartoma demonstrates a classic appearance. Atypical lesions may still require additional evaluation.
4. Granulomatous Disease
Healed granulomatous infection is a common cause of calcified pulmonary nodules.
A history of prior infection, calcified lymph nodes, and additional characteristic pulmonary findings may support this diagnosis.
Classic central or diffuse calcification is more reassuring than eccentric calcification.
5. Nodular Pulmonary Amyloidosis
Nodular pulmonary amyloidosis should be considered when a pulmonary nodule demonstrates:
Calcification
Irregular or spiculated margins
Solitary or multiple nodules
FDG uptake
Imaging features that remain suspicious despite the presence of calcification
The diagnosis generally cannot be established reliably from imaging alone. Tissue diagnosis and amyloid typing may be required.
Diagnostic Strategy: CT, PET/CT, and Tissue Diagnosis
CT and PET/CT provide complementary information.
CT is particularly useful for evaluating:
Nodule size
Location
Margin morphology
Calcification pattern
Internal architecture
Relationship to pleura and chest wall
FDG PET/CT provides information about metabolic activity and can help assess the likelihood of malignancy.
But neither modality independently establishes nodular pulmonary amyloidosis.
When imaging remains suspicious for malignancy, the clinical decision may require tissue diagnosis.
Histologic evaluation can demonstrate amyloid deposition. Congo red staining may support the diagnosis, with characteristic optical findings under polarized light. Once amyloid is confirmed, determining the protein type becomes important.
Localized Pulmonary Amyloidosis Versus Systemic Amyloidosis
This distinction is one of the most clinically important lessons in the case.
A diagnosis of nodular pulmonary amyloidosis does not automatically mean that the patient has systemic amyloidosis.
Conversely, the appearance of a localized pulmonary lesion does not eliminate the need for systemic evaluation when the clinical context warrants it.
Depending on the clinical situation, evaluation may include:
Serum and urine monoclonal protein studies
Free light-chain testing
Renal function assessment
Cardiac evaluation
Electrocardiography
Echocardiography when clinically indicated
The patient's arrhythmia and conduction abnormalities make cardiac assessment clinically relevant, but they do not by themselves establish cardiac amyloidosis.
Treatment: Does Every Amyloid Pulmonary Nodule Need Surgery?
No.
Treatment depends on:
Diagnostic certainty
Symptoms
Lesion characteristics
Localized versus systemic disease
Evidence of progression
Overall health
Procedural risk
Patient preferences
When nodular pulmonary amyloidosis is localized, asymptomatic, and adequately established, clinical and imaging surveillance may be appropriate.
Surgery or additional tissue sampling may be considered when malignancy remains uncertain, the lesion grows, or symptoms develop.
If systemic AL amyloidosis is identified, management shifts toward evaluation and treatment of the underlying plasma-cell disorder rather than treating the pulmonary nodule as an isolated lesion.
Prognosis and Follow-Up
Localized nodular pulmonary amyloidosis may remain stable for prolonged periods or progress slowly.
However, some lesions may enlarge or change in appearance, and imaging alone cannot perfectly predict future behavior.
Follow-up should therefore be individualized and may consider:
Lesion size
Morphologic change
Development of additional nodules
New respiratory symptoms
Associated autoimmune or lymphoproliferative disease
Evidence suggesting systemic amyloid involvement
The key principle is to keep radiologic assessment of the pulmonary lesion conceptually separate from assessment for systemic amyloidosis.
Diagnostic Risk: Where Can Errors Occur?
This case illustrates several potential sources of diagnostic error.
Anchoring on calcification
The opposite errors are both possible:
“There is calcification, so this must be benign.”
“There is spiculation and FDG uptake, so this must be cancer.”
Both statements are too absolute.
Overinterpreting SUVmax
An SUVmax of 4.7 is meaningful as evidence of increased metabolic activity, but it is not a histologic diagnosis.
Single-plane interpretation
Apical lesions can be difficult to characterize on one CT plane. Multiplanar review can clarify the relationship between the lesion, pleura, chest wall, and adjacent lung.
Failure to integrate pathology
When imaging remains suspicious, tissue diagnosis may be necessary because CT and PET/CT cannot reliably distinguish every rare benign mimic from malignancy.
Cognitive forcing
Once a lesion looks malignant, there is a risk of interpreting every subsequent finding as supporting cancer.
A better approach is:
Imaging finding → probability assessment → differential diagnosis → tissue confirmation when appropriate.
AI Perspective: What Could Medical Imaging AI Contribute?
This case is particularly relevant to the emerging role of artificial intelligence in chest imaging.
A radiology AI system could potentially assist with:
Pulmonary nodule detection
Detection of subtle apical nodules
Nodule localization
Measurement
Volumetric assessment
Comparison with prior examinations
Structured reporting
Workflow prioritization
Second-reader support
However, AI should not be expected to independently resolve the fundamental diagnostic problem presented here.
A system may identify a suspicious nodule, but recognizing nodular pulmonary amyloidosis as a rare mimic of lung cancer requires clinical context, imaging interpretation, differential diagnosis, and often pathology.
The appropriate role for AI is therefore closer to detection support, quantitative analysis, second reading, and workflow assistance than autonomous diagnosis. The ScholarGen MediAI framework specifically emphasizes these roles while requiring consideration of false positives, false negatives, domain shift, dataset bias, image quality, alert fatigue, generalization, and human oversight.
AI Workflow Implications
For a case like this, a clinically useful AI workflow could look like:
Chest radiograph
↓
Subtle apical abnormality detected
↓
CT correlation
↓
Pulmonary nodule detected and measured
↓
Morphologic characterization
Location
Size
Spiculation
Calcification
Pleural relationship
↓
Prior-image comparison
↓
PET/CT correlation when clinically indicated
↓
Risk assessment
↓
Radiologist interpretation
↓
Biopsy or follow-up according to clinical context
The important point is that AI should support the workflow without removing human diagnostic responsibility.
A system that merely flags “possible lung nodule” may be useful.
A system that also helps ensure that the radiologist sees prior examinations, accurately measures the lesion, recognizes change over time, and maintains a structured differential could potentially provide greater clinical value.
Healthcare System and Workflow Impact
Rare mimics such as nodular pulmonary amyloidosis create a specific workflow challenge.
The problem is not simply whether an AI system can detect a nodule.
The larger question is:
Can the imaging workflow help clinicians reach the correct diagnosis without unnecessary delay or unnecessary procedures?
A suspicious pulmonary nodule may lead to additional CT imaging, PET/CT, biopsy, surgery, or prolonged surveillance.
Therefore, high-quality imaging interpretation has implications for:
Diagnostic efficiency
Additional testing
Procedure selection
Patient anxiety
Resource utilization
Radiologist workload
Turnaround time
The case supports a general principle: better diagnostic reasoning is not the same as more testing.
The objective is to obtain the information most likely to change management.
Fleischner Society Guidance: An Important Caveat
The Fleischner Society 2017 recommendations are widely used for incidentally detected pulmonary nodules in adults.
However, they are not universal rules.
They may not apply directly to certain populations, including patients with known cancer, immunocompromised patients, or patients undergoing lung cancer screening.
More importantly, when a nodule has unusual morphology such as eccentric calcification combined with spiculation, management should not be reduced to a size-based algorithm alone.
Clinical risk, imaging appearance, prior imaging, and diagnostic certainty all matter.
Practical Radiology Pearls
Pearl 1: Calcification is a pattern, not a diagnosis.
Do not label every calcified pulmonary nodule as benign.
Pearl 2: Eccentric calcification deserves attention.
Eccentric calcification does not reliably exclude malignancy.
Pearl 3: Spiculation increases suspicion but is not specific.
Some nonmalignant lesions can demonstrate irregular or spiculated margins.
Pearl 4: SUVmax is not a pathology report.
An SUVmax of 4.7 indicates increased metabolic activity in this case, not a definitive diagnosis of cancer.
Pearl 5: Review the lesion in multiple planes.
Apical lesions can be difficult to characterize on a single axial image.
Pearl 6: Tissue diagnosis may be necessary.
When imaging cannot reliably distinguish malignancy from a rare mimic, pathology can be decisive.
Pearl 7: Amyloid typing matters.
Once amyloid deposition is identified, determining the protein type is clinically important.
Pearl 8: Localized pulmonary amyloidosis is not synonymous with systemic amyloidosis.
The two diagnostic questions must be addressed separately.
Common Pitfalls
Pitfall 1: “It is calcified, so it is benign.”
False. Some malignant lesions and nonmalignant mimics can contain calcification.
Pitfall 2: “SUVmax > 2.5 means cancer.”
False. FDG uptake is not cancer-specific.
Pitfall 3: “Spiculation means lung cancer.”
Not necessarily. Spiculation raises suspicion but is not pathognomonic.
Pitfall 4: “A pulmonary amyloid diagnosis means systemic amyloidosis.”
Not necessarily. Localized and systemic disease must be distinguished.
Pitfall 5: “The arrhythmia explains the lung lesion.”
There is insufficient evidence to establish that relationship in this case.
Pitfall 6: “PET/CT eliminates the need for biopsy.”
No. PET/CT provides metabolic information but does not replace histologic diagnosis when tissue confirmation is clinically necessary.
Frequently Asked Questions
What is nodular pulmonary amyloidosis?
Nodular pulmonary amyloidosis is a form of pulmonary amyloidosis in which amyloid deposits form one or more localized pulmonary nodules. It can be discovered incidentally and may mimic primary lung cancer on CT.
Can nodular pulmonary amyloidosis look like lung cancer?
Yes. Nodules may demonstrate irregular or spiculated margins, calcification, and increased FDG uptake. These findings can substantially increase suspicion for malignancy.
Does calcification mean a lung nodule is benign?
No. The morphology and distribution of calcification matter. Central, diffuse, laminated, and classic popcorn-like patterns can support certain benign diagnoses, whereas eccentric or punctate calcification is less specific.
Can pulmonary amyloidosis show FDG uptake?
Yes. Increased FDG uptake has been described in nodular pulmonary amyloidosis. Therefore, metabolic activity alone cannot distinguish amyloidosis from malignancy.
What was the SUVmax in this case?
The reported SUVmax was 4.7. The important point is that this value demonstrated increased metabolic activity but did not establish malignancy.
Does AL amyloidosis always mean systemic amyloidosis?
No. The identification of AL-type amyloid requires appropriate clinical assessment for possible systemic involvement, but localized pulmonary amyloidosis and systemic AL amyloidosis should not automatically be treated as the same condition.
Is surgery always required?
No. Treatment depends on diagnostic certainty, symptoms, lesion behavior, systemic involvement, overall health, and procedural risk. Selected patients with well-established localized and asymptomatic disease may be followed clinically and radiologically.
Key Takeaways
Nodular pulmonary amyloidosis is an important but uncommon mimic of lung cancer.
A calcified pulmonary nodule is not automatically benign.
Eccentric calcification combined with spiculation can remain suspicious for malignancy.
FDG uptake does not equal cancer. In this case, the nodule had an SUVmax of 4.7 despite the final diagnosis of nodular pulmonary amyloidosis.
CT morphology and PET metabolic activity should be interpreted together with clinical information.
Multiplanar CT review is particularly useful for apical and pleural-adjacent lesions.
When imaging cannot confidently establish the diagnosis, tissue sampling may be necessary.
Congo red staining and amyloid typing are important components of pathologic evaluation.
Localized pulmonary amyloidosis should be distinguished from systemic amyloidosis.
AI can support detection, measurement, comparison, prioritization, and second reading, but it does not eliminate diagnostic responsibility.
The central lesson is simple:
A suspicious pulmonary nodule should be interpreted as a probability problem, not a pattern-matching shortcut.
Continue Learning
CT Evaluation of Pulmonary Nodules and Lung Cancer Differential Diagnosis
[INTERNAL LINK PLACEHOLDER]Calcified Pulmonary Nodules: Central, Diffuse, Popcorn, Punctate, and Eccentric Patterns
[INTERNAL LINK PLACEHOLDER]How to Interpret F-18 FDG PET/CT and SUVmax in Pulmonary Nodules
[INTERNAL LINK PLACEHOLDER]Pulmonary Hamartoma and Granulomatous Nodules: CT Differential Diagnosis
[INTERNAL LINK PLACEHOLDER]Systemic AL Amyloidosis and Cardiac Involvement: Imaging and Clinical Evaluation
[INTERNAL LINK PLACEHOLDER]
References
Khan AN, Al-Jahdali HH, Allen CM, et al. The calcified lung nodule: What does it mean? Annals of Thoracic Medicine. 2010;5(2):67–79. doi:10.4103/1817-1737.62469.
MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. Radiology. 2017;284(1):228–243. doi:10.1148/radiol.2017161659.
Czeyda-Pommersheim F, Hwang M, Chen SS, et al. Amyloidosis: Modern cross-sectional imaging. RadioGraphics. 2015;35(5):1381–1392. doi:10.1148/rg.2015140179.
Milani P, Basset M, Russo F, et al. The lung in amyloidosis. European Respiratory Review. 2017;26(145):170046. doi:10.1183/16000617.0046-2017.
Core JM, Alsaad AA, Jiang L, et al. Nodular pulmonary amyloidosis: A complex disease with malignancy association. BMJ Case Reports. 2017. doi:10.1136/bcr-2017-220428.
Quan XQ, Yin TJ, Zhang CT, et al. (18)F-FDG PET/CT in patients with nodular pulmonary amyloidosis: Case report and literature review. Case Reports in Oncology. 2014;7(3):789–798. doi:10.1159/000369128.
Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: Chemical identification and clinical classification—International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209–213. doi:10.1080/13506129.2016.1257986.
Urban BA, Fishman EK, Goldman SM, et al. CT evaluation of amyloidosis: Spectrum of disease. RadioGraphics. 1993;13(6):1295–1308. doi:10.1148/radiographics.13.6.8290728.
Cruickshank A, Stieler G, Ameer F. Evaluation of the solitary pulmonary nodule. Internal Medicine Journal. 2019;49(3):306–315. doi:10.1111/imj.14219.
Moy LN, Mirza M, Moskal B, et al. Pulmonary AL amyloidosis: A review and update on treatment options. Annals of Medicine and Surgery. 2022;80:104060. doi:10.1016/j.amsu.2022.104060.
The reference list above is derived from the case-study source; DOI details are retained only where supplied in that source.
Medical Disclaimer
This article is intended for medical education and informational purposes only. It is not a substitute for professional medical diagnosis, treatment, or individualized clinical decision-making. Patients should discuss symptoms, imaging findings, biopsy results, and treatment options with their qualified healthcare professionals.
Comments
Post a Comment